Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer

被引:44
作者
Kanakis, I
Nikolaou, M
Pectasides, D
Kiamouris, C
Karamanos, NK [1 ]
机构
[1] Univ Patras, Dept Chem, Biochem Lab, GR-26500 Patras, Greece
[2] Metaxas Mem Hosp, Dept Med Oncol, Piraeus 18537, Greece
[3] Univ Athens, Dept Epidemiol, Athens, Greece
关键词
breast cancer; bone metastasis; tumor biochemical markers; bone-specific alkaline phosphatase; collagen; 1; N-telopeptide;
D O I
10.1016/S0731-7085(03)00567-3
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Bone metastasis is a frequent complication of cancer disease. The metastatic spread of cancer to bone is common to many different malignancies, particularly breast (ca. 73%), prostate (ca. 68%) and lung (ca. 36%) cancers. Metastases to bone cause increased bone resorption both from direct effects of the tumor itself and thought osteoclastic activation. The diagnosis and follow-up of bone metastatic cancer patients usually relies on skeletal X-ray and bone scintigraphy. However, the development of biochemical markers, used as indicators of bone metabolism, provides data useful in the clinical practice. The most important markers for bone remodeling process, bone formation and resorption, are bone-specific alkaline phosphatase (BAP) and N-telopeptide of type I collagen (NTx), respectively. In this report, we applied two solid-phase immunoassays used for the determination of BAP and NTx in serum of breast cancer (BC) post-menopausal women with bone metastasis and healthy individuals. BAP level in patients was found to be 45.72 +/- 12.92 U/l, while the normal range for healthy individuals was 14.2 - 42.7 U/l. The respective level of serum NTx was 19.20 +/- 8.87 nM bone collagen equivalents (BCE) for patients and 15.9 +/- 3.8 nM BCE for healthy women. Correlation of the obtained data showed elevated levels for both markers indicating high rate of bone degradation in breast metastatic cancer. (C) 2003 Elsevier B.V All rights reserved.
引用
收藏
页码:827 / 832
页数:6
相关论文
共 18 条
[1]  
Berruti A, 1999, CLIN CHEM, V45, P1240
[2]   Biochemical markers of bone metabolism: An overview [J].
Christenson, RH .
CLINICAL BIOCHEMISTRY, 1997, 30 (08) :573-593
[3]  
CHRISTENSON RH, 1996, ISOENZYMES ISOFORMS, P1077
[4]   Recent trends in US breast cancer incidence, survival, and mortality rates [J].
Chu, KC ;
Tarone, RE ;
Kessler, LG ;
Ries, LAG ;
Hankey, BF ;
Miller, BA ;
Edwards, BK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1571-1579
[5]  
Clemens JD, 1997, CLIN CHEM, V43, P2058
[6]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[7]  
DEMERS LM, 1995, CLIN CHEM, V41, P1489
[8]  
FRENAY M, 1988, B CANCER, V75, P533
[9]   STRUCTURE OF PYRIDINOLINE, A COLLAGEN CROSSLINK [J].
FUJIMOTO, D ;
MORIGUCHI, T ;
ISHIDA, T ;
HAYASHI, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1978, 84 (01) :52-57
[10]   COMPARISON OF NEW BIOCHEMICAL MARKERS OF BONE TURNOVER IN LATE POSTMENOPAUSAL OSTEOPOROTIC WOMEN IN RESPONSE TO ALENDRONATE TREATMENT [J].
GARNERO, P ;
SHIH, WCJ ;
GINEYTS, E ;
KARPF, DB ;
DELMAS, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) :1693-1700